Disease-modifying drugs for Alzheimer disease: implications for people in Canada.

Jennifer A Watt Wanrudee Isaranuwatchai Linda Grossman Sharon E Straus

CMAJ

Knowledge Translation Program (Watt, Isaranuwatchai, Straus), Li Ka Shing Knowledge Institute, St. Michael's Hospital; Division of Geriatric Medicine (Watt, Straus), Department of Medicine, University of Toronto, Toronto, Ont.; Health Intervention and Technology Assessment Program (Isaranuwatchai), Ministry of Public Health, Nonthaburi, Thailand; Patient partner (Grossman), Toronto, Ont.

Published: October 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615338	PMC
http://dx.doi.org/10.1503/cmaj.230595	DOI Listing

Publication Analysis

Top Keywords

disease-modifying drugs

drugs alzheimer

alzheimer disease

disease implications

implications people

people canada

disease-modifying

alzheimer

disease

implications

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!